Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report published on Saturday. The firm issued a hold rating on the medical research company’s stock.

Several other equities analysts have also recently commented on the stock. HC Wainwright reissued a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a research report on Monday, November 11th. D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Price Performance

CTSO opened at $1.09 on Friday. The firm has a market cap of $59.60 million, a price-to-earnings ratio of -3.03 and a beta of 0.61. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The stock’s 50-day moving average price is $1.02 and its 200 day moving average price is $1.04. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.61.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Millennium Management LLC acquired a new stake in Cytosorbents during the 4th quarter worth $30,000. Renaissance Technologies LLC grew its holdings in shares of Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after purchasing an additional 8,400 shares during the last quarter. Northern Trust Corp increased its position in shares of Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after purchasing an additional 16,701 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Cytosorbents in the 4th quarter valued at about $99,000. Finally, Geode Capital Management LLC boosted its position in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.